Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber 

Published byAda Mikkonen Modified over 5 years ago

Similar presentations

Presentation on theme: "Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber "— Presentation transcript:

1 Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber  Michel Roux, MD, Philippe Devillier, MD, PhD, William H. Yang, MD, Armelle Montagut, MSc, Kathy Abiteboul, PharmD, Agnès Viatte, MSc, Robert K. Zeldin, MD  Journal of Allergy and Clinical Immunology  Volume 138, Issue 2, Pages e5 (August 2016) DOI: /j.jaci Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Trial design. After the primary screening based on clinical history of HDM-associated allergic rhinitis, eligible subjects underwent a baseline HDM allergen challenge in an EEC. Those with symptom scores above the predefined threshold were randomized to 1 of the 4 treatment arms, and underwent 4 additional allergen challenges during the 6 treatment months. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Subject disposition. *Recorded as withdrawal by subject. †Sponsor's decision to withdraw the subject. ‡Subject did not tolerate the chamber. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Treatment efficacy. Change from baseline (ChBL) to end of treatment (after 6 months) in the AUC of RTSSs for the full 4 hours (0-4 h) (A) or the last 2 hours (2-4 h) (B) of allergen challenge. Change from baseline (ChBL) in the ARTSSs for the full 4 hours (0-4 h) (C) or the last 2 hours (2-4 h) (D) of allergen challenge. NS, Not significant. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 Assessment of RTSSs during HDM allergen challenge. Subjects were exposed to HDM allergens for 4 hours in the EEC. Rhinitis symptoms were recorded by the subjects at 13 time points, and RTSSs (range, 0-12) were derived at each time point. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 Immunological markers. Serum-specific IgE (top panels) and IgG4 (bottom panels) levels for D pteronyssinus and D farinae at baseline and after 2, 4, and 6 months. Units: kU/L for IgE, μg/mL for IgG4. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber "

Similar presentations

Detection of novel occupational wood allergens in locust wood dust (Robinia pseudoacacia L.)  Sabine Kespohl, PhD, Rolf Merget, MD, Axel Overlack, MD,

Detection of novel occupational wood allergens in locust wood dust (Robinia pseudoacacia L.)  Sabine Kespohl, PhD, Rolf Merget, MD, Axel Overlack, MD,
Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication 

Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication 
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
Stacie M. Jones, MD, Scott H. Sicherer, MD, A

Stacie M. Jones, MD, Scott H. Sicherer, MD, A
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood  Zaraquiza Zolkipli, MSc,

Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood  Zaraquiza Zolkipli, MSc,
Julie Wang, MD, James H. Godbold, PhD, Hugh A. Sampson, MD 

Julie Wang, MD, James H. Godbold, PhD, Hugh A. Sampson, MD 
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Similar presentations

Ads by Google